Letrozole Versus Laparoscopic Ovarian Drilling in Polycystic Ovary Syndrome
Letrozole Versus Laparoscopic Ovarian Drilling for Clomiphene-resistant Women With Polycystic Ovary Syndrome
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Assiut, Egypt
- Recruiting
- Assiut University
-
Contact:
- Ahmed Abbas, MD
- Phone Number: 00201003385183
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- History of at least one year of infertility either primary or secondary.
- Body mass index: 25-35
- Normal fallopian tubes
- Normal semen analysis of the husband
- Women who will accept to participate in the study
Exclusion Criteria:
- Body mass index above 35
- Contraindication to general anesthesia
- Previous laparoscopic drilling
- Presence of other causes of infertility
- Women who had received metformin, gonadotrophin, oral contraceptives or other hormonal drugs during the preceding 6 months
- Women who intended to start a diet program
- Women who will refuse to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: letrozole
letrozole 2.5 mg oral tablets will be started daily from day 3 of the menses for 5 days in a dose of 5 mg/day
|
oral tablets 2.5 mg
Other Names:
|
|
Active Comparator: laparoscopic drilling
laparoscopy will be performed using three-puncture technique.
Each ovary will be cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using a monopolar electrosurgical needle
|
laparoscopic electrocauterization
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The ovulation rate
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The mid-cyclic endometrial thickness
Time Frame: one day
|
one day
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Endocrine System Diseases
- Ovarian Cysts
- Cysts
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Polycystic Ovary Syndrome
- Infertility
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Letrozole
Other Study ID Numbers
Other Study ID Numbers
- LEVOD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
NCT01936077CompletedInfertility, Female Infertility, Male Infertility
-
NCT00315029CompletedPregnancy | Male Infertility | Female Infertility
-
NCT02107521TerminatedMale Infertility | Female Infertility
-
NCT03670758UnknownUnexplained Female Infertility
-
NCT04945265Not yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
NCT03323801CompletedMale Infertility, Azoospermia
-
NCT01331395TerminatedPrimary Female Infertility | Secondary Female Infertility
-
NCT01859520CompletedMale Infertility | Unexplained Infertility
-
NCT07611448Enrolling by invitationInfertility (IVF Patients) | Infertility Assisted Reproductive Technology
-
NCT04184323WithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, Nonimplantation
Clinical Trials on Letrozole
-
NCT07401381Not yet recruitingHormone Receptor Positive Early Breast Cancer
-
NCT07635082CompletedPolycystic Ovary Syndrome | Polycystic Ovary Syndrome (PCOS) Women
-
NCT07225790Completed
-
NCT01797718CompletedConstitutional Delay of Growth and Puberty
-
NCT07285382RecruitingHR Positive HER2 Negative Advanced Breast Cancer
-
NCT05454358Terminated
-
NCT07274709Completed
-
NCT04568616Active, not recruitingBreast Cancer | ER Positive Breast Cancer
-
NCT06315205Active, not recruiting